Ikarian Capital, LLC Nektar Therapeutics Call Options Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 12, 2022	SELL	$3.17 - $6.17 $424,463 - $826,163	-133,900 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$4.16 - $13.72 $482,976 - $1.59 Million	-116,100 Reduced 46.44%	133,900 $722,000
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $1.46 Million - $2.49 Million	135,200 Added 117.77%	250,000 $3.38 Million
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $1.5 Million - $2.16 Million	114,800 New	114,800 $2.06 Million
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $2.48 Million - $3.82 Million	-150,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $2.53 Million - $3.52 Million	150,000 New	150,000 $3.47 Million

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.